They might need to prove out potential efficacy a little more for W.lymphoma before they land partner. I don't think the psoriasis data alone will be strong enough - but the proof that they can exert targeted tlr activity where it's needed for 90% of the W.lymphoma cases will stir some interest I think. Actually, given BB's and Third Rock Investments involvement - I'd say it already has.
News 
Market Data 
Discover 
